LC3-Binding Macrocyclic Peptides for Selective Autophagy Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current autophagy inhibitors, such as chloroquine and hydroxychloroquine, are non-specific, have poor efficacy, unfavorable pharmacokinetics, and cause high normal-tissue toxicity due to their disruption of essential cellular processes, necessitating the development of targeted inhibitors that can selectively inhibit autophagy without affecting normal tissue.
Innovation Solution
Macrocyclic peptides that bind to LC3, inhibit LC3-mediated protein-protein interactions, and are designed to be cell-permeable, protease-resistant, and labeled with fluorophores for molecular imaging, thereby inhibiting autophagosome elongation/maturation and autophagic flux.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific autophagy inhibitors like chloroquine and hydroxychloroquine are used, then autophagy can be inhibited, but normal tissue toxicity increases and efficacy decreases
Solution Approach 1:
The patent introduces a targeted delivery system using antibodies or ligands that specifically bind to tumor cell surface markers, serving as intermediaries to deliver the autophagy inhibitor selectively to cancer cells while sparing normal tissue. This mediator approach resolves the contradiction by enabling effective autophagy inhibition in tumors without causing systemic toxicity to healthy organs.
Solution Approach 2:
The invention applies local quality by modifying the inhibitor to have different properties in different locations: it remains inactive or has reduced activity in normal tissue, but becomes activated or highly effective specifically within the tumor microenvironment. This spatial differentiation of inhibitor activity allows selective cancer cell killing while protecting normal tissue from harmful effects.
2Reliability
If non-specific lysosomotropic agents are used to inhibit autophagy, then autophagic flux is blocked, but pharmacokinetics become unfavorable and treatment efficacy is poor
Solution Approach 1:
The patent employs targeted delivery vehicles or conjugates that act as intermediaries to transport the autophagy inhibitor specifically to tumor cells. This targeted approach improves treatment efficacy by concentrating the inhibitor where it is needed while reducing off-target effects, thereby resolving the contradiction between achieving sufficient autophagy blockade and maintaining favorable pharmacokinetics.
Solution Approach 2:
The invention alters key pharmacokinetic parameters such as half-life, distribution volume, and tissue penetration by modifying the inhibitor's chemical structure or delivery system. These parameter changes enable the drug to achieve and maintain effective concentrations in tumors while minimizing exposure to normal tissues, thus improving both autophagy blockade effectiveness and overall treatment efficacy.
3Reliability
If autophagy is inhibited in cancer cells, then chemotherapy resistance is reduced, but normal tissue dependent on autophagy may be damaged
Solution Approach 1:
The patent uses targeted delivery systems with antibodies or ligands specific to tumor cell surface markers as intermediaries. These intermediaries guide the autophagy inhibitor exclusively to cancer cells, enabling chemotherapy sensitization in tumors while preventing damage to normal tissues that rely on autophagy for survival, thereby resolving the contradiction between therapeutic benefit and tissue safety.
Solution Approach 2:
The invention implements local quality by creating a spatially differentiated effect where autophagy inhibition is strongly activated in the tumor microenvironment but remains minimal in normal tissues. This localized action allows the treatment to sensitize cancer cells to chemotherapy without causing harmful effects to healthy organs that depend on autophagic processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The macrocyclic peptides effectively inhibit autophagy in cancer cells, restoring cellular growth in chemotherapy-resistant tumors and visualizing autophagosome formation, while showing no apparent toxicity at mid-micromolar concentrations, thus enhancing chemotherapy and radiotherapy efficacy and providing targeted imaging.
Implementation Method 1
inhibit LC3-mediated protein-protein interactions
Implementation Method 2
Labeling these peptides with a fluorophore (e.g., fluorescein or rhodamine) can be used to generate molecular imaging probes to visualize autophagosomes in living cells
Data Source
AI summary
Provided herein are cyclic peptide inhibitors of autophagy that bind to LC3. These cyclic peptides may be used to treat diseases or disorders associated with autophagy, such as, for example, cancer, diabetes, cardiovascular disease, and neurological disorders. These cyclic peptides may also be used to sensitize cancers to front-line chemotherapy, immunotherapy, and/or radiation therapy.